Serology- and PCR-based Cumulative Incidence of SARS-CoV-2 Infection in Adults in a Successfully Contained Early Hotspot (CoMoLo Study), Germany, May to June 2020

Overview

Journal Euro Surveill

Specialty Infectious Diseases

Date 2020 Nov 27

PMID 33243353

Citations 38

Authors

Claudia Santos-Hovener

Hannelore K Neuhauser

Angelika Schaffrath Rosario

Markus Busch

Martin Schlaud

Robert Hoffmann

Antje Gosswald

Carmen Koschollek

Jens Hoebel

Jennifer Allen

Antje Haack-Erdmann

Stefan Brockmann

Thomas Ziese

Andreas Nitsche

Janine Michel

Sebastian Haller

Hendrik Wilking

Osamah Hamouda

Victor M Corman

Christian Drosten

Lars Schaade

Lothar H Wieler

Thomas Lampert

Affiliations

Soon will be listed here.

Abstract

Three months after a coronavirus disease (COVID-19) outbreak in Kupferzell, Germany, a population-based study (n = 2,203) found no RT-PCR-positives. IgG-ELISA seropositivity with positive virus neutralisation tests was 7.7% (95% confidence interval (CI): 6.5-9.1) and 4.3% with negative neutralisation tests. We estimate 12.0% (95% CI: 10.4-14.0%) infected adults (24.5% asymptomatic), six times more than notified. Full hotspot containment confirms the effectiveness of prompt protection measures. However, 88% naïve adults are still at high COVID-19 risk.

Citing Articles

Cross-Species Surveillance of Respiratory Viruses in Domestic and Wild Mammals of an Urban Atlantic Forest from Brazil.

da Silva Junior L, Wailante D, Bueno M, Moura P, Pauvolid-Correa A, Novaes R Ecohealth. 2025; 22(1):11-28.

PMID: 39904935 PMC: 11890330. DOI: 10.1007/s10393-024-01691-w.

Development and evaluation of a lyophilization protocol for colorimetric RT-LAMP diagnostic assay for COVID-19.

Prado N, Marin A, Lalli L, Sanchuki H, Wosniaki D, Nardin J Sci Rep. 2024; 14(1):10612.

PMID: 38719936 PMC: 11078981. DOI: 10.1038/s41598-024-61163-7.

A bead-based multiplex assay covering all coronaviruses pathogenic for humans for sensitive and specific surveillance of SARS-CoV-2 humoral immunity.

Stern D, Meyer T, Treindl F, Mages H, Kruger M, Skiba M Sci Rep. 2023; 13(1):21846.

PMID: 38071261 PMC: 10710470. DOI: 10.1038/s41598-023-48581-9.

Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January-December 2020.

Vaughan A, Duffell E, Freidl G, Lemos D, Nardone A, Valenciano M BMJ Open. 2023; 13(11):e064240.

PMID: 37931969 PMC: 10632881. DOI: 10.1136/bmjopen-2022-064240.

Long-term health consequences among individuals with SARS-CoV-2 infection compared to individuals without infection: results of the population-based cohort study CoMoLo Follow-up.

Heidemann C, Sarganas G, Du Y, Gaertner B, Poethko-Muller C, Cohrdes C BMC Public Health. 2023; 23(1):1587.

PMID: 37605232 PMC: 10440884. DOI: 10.1186/s12889-023-16524-8.

References

Knabl L, Mitra T, Kimpel J, Rossler A, Volland A, Walser A . High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl. Commun Med (Lond). 2021; 1(1):4. PMC: 8633917. DOI: 10.1038/s43856-021-00007-1. View

Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G . Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine. 2020; 29:100651. PMC: 7676374. DOI: 10.1016/j.eclinm.2020.100651. View

Long Q, Tang X, Shi Q, Li Q, Deng H, Yuan J . Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200-1204. DOI: 10.1038/s41591-020-0965-6. View

Chen X, Chen Z, Azman A, Deng X, Sun R, Zhao Z . Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health. 2021; 9(5):e598-e609. PMC: 8049592. DOI: 10.1016/S2214-109X(21)00026-7. View

Aziz N, Corman V, Echterhoff A, Muller M, Richter A, Schmandke A . Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun. 2021; 12(1):2117. PMC: 8035181. DOI: 10.1038/s41467-021-22351-5. View

Pollan M, Perez-Gomez B, Pastor-Barriuso R, Oteo J, Hernan M, Perez-Olmeda M . Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020; 396(10250):535-544. PMC: 7336131. DOI: 10.1016/S0140-6736(20)31483-5. View

Gudbjartsson D, Norddahl G, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E . Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. 2020; 383(18):1724-1734. PMC: 7494247. DOI: 10.1056/NEJMoa2026116. View

Corman V, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu D . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3). PMC: 6988269. DOI: 10.2807/1560-7917.ES.2020.25.3.2000045. View

Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y . Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26(6):845-848. DOI: 10.1038/s41591-020-0897-1. View

10.

Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel K . Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020; 5(12):1598-1607. PMC: 7610833. DOI: 10.1038/s41564-020-00813-8. View

11.

Wolfel R, Corman V, Guggemos W, Seilmaier M, Zange S, Muller M . Virological assessment of hospitalized patients with COVID-2019. Nature. 2020; 581(7809):465-469. DOI: 10.1038/s41586-020-2196-x. View

12.

Houlihan C, Beale R . The complexities of SARS-CoV-2 serology. Lancet Infect Dis. 2020; 20(12):1350-1351. PMC: 7511169. DOI: 10.1016/S1473-3099(20)30699-X. View

13.

Rosenberg E, Tesoriero J, Rosenthal E, Chung R, Barranco M, Styer L . Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. 2020; 48:23-29.e4. PMC: 7297691. DOI: 10.1016/j.annepidem.2020.06.004. View

14.

Percivalle E, Cambie G, Cassaniti I, Nepita E, Maserati R, Ferrari A . Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill. 2020; 25(24). PMC: 7315724. DOI: 10.2807/1560-7917.ES.2020.25.24.2001031. View

15.

Poethko-Muller C, Prutz F, Buttmann-Schweiger N, Fiebig J, Sarganas G, Seeling S . German and international studies on SARS-CoV-2 seroprevalence. J Health Monit. 2022; 5(Suppl 4):2-15. PMC: 8734155. DOI: 10.25646/7024. View

16.

Streeck H, Schulte B, Kummerer B, Richter E, Holler T, Fuhrmann C . Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nat Commun. 2020; 11(1):5829. PMC: 7672059. DOI: 10.1038/s41467-020-19509-y. View

17.

Ibarrondo F, Fulcher J, Goodman-Meza D, Elliott J, Hofmann C, Hausner M . Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 2020; 383(11):1085-1087. PMC: 7397184. DOI: 10.1056/NEJMc2025179. View

18.

Rogan W, Gladen B . Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978; 107(1):71-6. DOI: 10.1093/oxfordjournals.aje.a112510. View